316 related articles for article (PubMed ID: 32414649)
1. Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer.
Zhang X; Yang H
Clin Breast Cancer; 2020 Aug; 20(4):275-282. PubMed ID: 32414649
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNAs engender drug resistance to different subtypes of treatments of breast cancers and may provide a "next generation" therapy option.
Chen WT; Wu HT; Shen JX; Ye QQ; Zhang ML; Chen WJ; Liu J
Discov Med; 2020; 29(156):27-39. PubMed ID: 32598860
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNAs AC026904.1 and UCA1: a "one-two punch" for TGF-β-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer.
Li GY; Wang W; Sun JY; Xin B; Zhang X; Wang T; Zhang QF; Yao LB; Han H; Fan DM; Yang AG; Jia LT; Wang L
Theranostics; 2018; 8(10):2846-2861. PubMed ID: 29774079
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer.
Li Y; Jiang B; Zhu H; Qu X; Zhao L; Tan Y; Jiang Y; Liao M; Wu X
Tumour Biol; 2017 Jun; 39(6):1010428317705790. PubMed ID: 28635401
[TBL] [Abstract][Full Text] [Related]
6. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.
Peng L; Jiang J; Tang B; Nice EC; Zhang YY; Xie N
Theranostics; 2020; 10(23):10360-10377. PubMed ID: 32929354
[TBL] [Abstract][Full Text] [Related]
7. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
9. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia.
Richards EJ; Zhang G; Li ZP; Permuth-Wey J; Challa S; Li Y; Kong W; Dan S; Bui MM; Coppola D; Mao WM; Sellers TA; Cheng JQ
J Biol Chem; 2015 Mar; 290(11):6857-67. PubMed ID: 25605728
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNAs as regulators of epithelial mesenchymal transition in breast cancer: A recent review.
El-Ashmawy NE; Khedr EG; Abo-Saif MA; Hamouda SM
Life Sci; 2024 Jan; 336():122339. PubMed ID: 38097110
[TBL] [Abstract][Full Text] [Related]
12. LncRNA expression signatures of twist-induced epithelial-to-mesenchymal transition in MCF10A cells.
Hu P; Yang J; Hou Y; Zhang H; Zeng Z; Zhao L; Yu T; Tang X; Tu G; Cui X; Liu M
Cell Signal; 2014 Jan; 26(1):83-93. PubMed ID: 24113349
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
14. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
15. Newly identified lncRNA-45 promotes breast cancer metastasis through activating the mTOR signaling pathway.
Qiu J; Guo Y; Wang S; Ren Q; Dong Z; Gao M; Ma J; Chen S; Liu S
Biochem Biophys Res Commun; 2023 Jan; 640():40-49. PubMed ID: 36502630
[TBL] [Abstract][Full Text] [Related]
16. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
Wang Y; Zhang M; Wang Z; Guo W; Yang D
Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
[TBL] [Abstract][Full Text] [Related]
17. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
18. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
[TBL] [Abstract][Full Text] [Related]
20. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
Venkatesh J; Wasson MD; Brown JM; Fernando W; Marcato P
Cancer Lett; 2021 Jul; 509():81-88. PubMed ID: 33848519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
